Cesar Rodriguez, MD

Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.

A panel of experts on multiple myeloma discuss dermatologic adverse effects seen in patients receiving talquetamab, including nail toxicities.

Multiple myeloma specialists discuss patient education approaches regarding the management of oral toxicity stemming from talquetamab treatment and outline potential research approaches.

Following a review of oral adverse events, the expert panel discusses how to manage oral toxicities seen in patients with multiple myeloma who are treated with talquetamab.

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.

The panel discusses the safety profile of talquetamab for patients with relapsed/refractory multiple myeloma.

Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.

The expert panel provides an overview of relapsed/refractory multiple myeloma, with a focus on current therapeutic options and unmet needs in the treatment space.

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.

Leading experts discuss the evolving landscape of myeloma immunotherapy, highlighting the potential of CAR-T and bispecifics and emphasizing the need for effective management of related toxicities to enhance patient outcomes.

Explore the critical aspects of counseling patients on the expectations and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T therapy.

Expert panelists review the complex decision-making process between CAR-T and BCMA bispecific therapies in the management of relapsed myeloma, discussing patient-specific factors and relative risks and benefits.

A complex case study in multiple myeloma management, exploring treatment sequencing options for a patient with a long history of disease and multiple lines of therapy.

Gain insight into strategies for monitoring for ICANS and CRS in myeloma treatment, including inpatient and outpatient administration, tocilizumab, dexamethasone, and impact on patient care.

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

Explore the potential in earlier use of novel therapy in multiple myeloma, including immunotherapy, bispecifics, and CAR-T therapies, with promising responses and potential paradigm shifts.

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.